{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T06:42:37Z","timestamp":1794120157247,"version":"4.8.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016169","name":"\u00d6sterreichische Gesellschaft f\u00fcr Knochen und Mineralstoffwechsel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100016169","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In dermatomyostis (DM) patients, inflammation, reduced activity, and medication have a negative impact on the musculoskeletal system. Several endocrine factors are involved in muscle growth and bone turnover.<\/jats:p>\n                    <jats:p>Objective: We aimed to investigate factors regulating myogenesis and bone metabolism and to evaluate possible associations between these endocrine factors, muscle strength, and functional tests in DM patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cross-sectional study in 20 dermatomyositis patients. Serum levels of myostatin (MSTN), follistatin (FSTN), dickkopf 1 (Dkk1), sclerostin (SOST), periostin (PSTN), the receptor activator nuclear factor kB ligand (RANKL):osteoprotegerin (OPG) ratio and fibroblast growth factor 23 (FGF23) were determined. Physical function was evaluated by hand-held strength measurement, chair rising test, timed up and go test and the 3-min walking test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Serum MSTN and FGF23 levels (2.5 [1.9; 3.2] vs. 1.9 [1.6; 2.3] and 2.17 [1.45; 3.26] vs. 1.28 [0.79; 1.96], respectively;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u2009\u00a00.05) were significantly higher in DM patients than in controls. Dkk1 was significantly lower (11.4 [6.9; 20.0] vs. 31.8 [14.3; 50.6],\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u2009\u00a00.01). Muscle strength and physical function tests correlated with each other (e.g. hip flexion \u2013 timed up and go test:\n                      <jats:italic>r<\/jats:italic>\n                      \u00a0=\u2009\u2212\u20090.748,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In DM patients, biochemical musculo-skeletal markers are altered and physical function shows deficits. All these tests reflect independent of each other different deficits in long-term DM patients which is important for the assessment of DM patients as well as planning of therapeutic interventions in clinical routine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12891-021-04030-0","type":"journal-article","created":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T23:28:35Z","timestamp":1612740515000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Myostatin and markers of bone metabolism in dermatomyositis"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1128-7532","authenticated-orcid":false,"given":"Katharina","family":"Kerschan-Schindl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Gruther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"F\u00f6ger-Samwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bangert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kudlacek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Pietschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"issue":"6","key":"4030_CR1","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/00002281-200111000-00001","volume":"13","author":"IE Lundberg","year":"2001","unstructured":"Lundberg IE. Idiopathic inflammatory myopathies: why do the muscles become weak? Curr Opin Rheumatol. 2001;13(6):457\u201360.","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"4030_CR2","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1002\/art.34625","volume":"64","author":"W Coley","year":"2012","unstructured":"Coley W, Rayavarapu S, Pandey GS, Sabina RL, Van der Meulen JH, Ampong B, et al. The molecular basis of skeletal muscle weakness in a mouse model of inflammatory myopathy. Arthitis Rheumatism. 2012;64(11):3750\u20139.","journal-title":"Arthitis Rheumatism"},{"issue":"6","key":"4030_CR3","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s00296-011-1821-2","volume":"32","author":"DC De Andrade","year":"2012","unstructured":"De Andrade DC, de Magalhaes Souza SC, de Carvalho JF, Takayama L, Borges CT, Aldrighi JM, et al. High frequency of osteoporosis and fractures in women with dermatomyositis\/polymyositis. Rheumatol Int. 2012;32(6):1549\u201353.","journal-title":"Rheumatol Int"},{"issue":"1","key":"4030_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s12020-015-0756-x","volume":"52","author":"CWS Lee","year":"2016","unstructured":"Lee CWS, Muo CH, Liang JA, Sung FC, Hsu CY, Kao CH. Increased osteoporosis risk in dermatomyositis or polymyositis independent of the treatments: a population-based cohort study with propensity score. Endocrine. 2016;52(1):86\u201392.","journal-title":"Endocrine."},{"key":"4030_CR5","doi-asserted-by":"publisher","first-page":"9079083","DOI":"10.1155\/2020\/9079083","volume":"2020","author":"V Mageriu","year":"2020","unstructured":"Mageriu V, Manole E, Bastian AE, Staniceanu F. Role of myokines in myositis pathogenesis and their potential to be new therapeutic targets in idiopatic inflammatory myopathies. J Immunol Res. 2020;2020:9079083. https:\/\/doi.org\/10.1155\/2020\/9079083.","journal-title":"J Immunol Res"},{"issue":"3","key":"4030_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3390\/diagnostics10030145","volume":"10","author":"FF Ramli","year":"2020","unstructured":"Ramli FF, Chin KY. A review of the potential application of osteocyte-related biomarkers, fibroblast growth Factor-23, Sclerostin, and Dickkopf-1 in predicting osteoporosis and fractures. Dignostics. 2020;10(3):145. https:\/\/doi.org\/10.3390\/diagnostics10030145.","journal-title":"Dignostics"},{"key":"4030_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.bone.2014.05.016","volume":"66","author":"P Garnero","year":"2014","unstructured":"Garnero P. New developments in biological markers of bone metabolism in osteoporosis. Bone. 2014;66:46\u201355.","journal-title":"Bone."},{"issue":"1","key":"4030_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000098223","volume":"143","author":"M Rauner","year":"2007","unstructured":"Rauner M, Sipos W, Pietschmann P. Osteoimmunology. Int Arch Allergy Immunol. 2007;143(1):31\u201348.","journal-title":"Int Arch Allergy Immunol"},{"key":"4030_CR9","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1093\/rheumatology\/kez651","volume":"59","author":"L Vernerova","year":"2020","unstructured":"Vernerova L, Horvathova V, Kropackova T, Vokurkova M, Klein M, Tomivik M, et al. Alterations in activing A-myostatin-follistatin system associate with disease activity in inflammatory myopathies. Rheumatology. 2020;59:2491\u2013501.","journal-title":"Rheumatology"},{"issue":"7","key":"4030_CR10","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). NEJM. 1975;292(7):344\u20137.","journal-title":"NEJM"},{"issue":"8","key":"4030_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). NEJM. 1975;292(8):403\u20137.","journal-title":"NEJM"},{"issue":"6","key":"4030_CR12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S8756-3282(03)00090-5","volume":"32","author":"S Kudlacek","year":"2003","unstructured":"Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P. Willvonseder R; Austrian study group on normative values of bone metabolism. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone. 2003;32(6):681\u20136.","journal-title":"Bone"},{"issue":"3","key":"4030_CR13","first-page":"473","volume":"22","author":"T Stoll","year":"1995","unstructured":"Stoll T, Br\u00fchlmann P, Stucki G, Seifert G, Seifert B, Michel BA. Muscle strength assessment in polymyositis and dermatomyositis evaluation of the reliability and clinical use of a new, quantitative, easily applicable method. J Rheumatol. 1995;22(3):473\u20137.","journal-title":"J Rheumatol"},{"issue":"3","key":"4030_CR14","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/ptj\/76.3.248","volume":"76","author":"AW Andrews","year":"1996","unstructured":"Andrews AW, Thomas MW, Bohannon RW. Normative values or isometric muscle force measurements obtained with hand-held dynamometers. Phys Ther. 1996;76(3):248\u201359.","journal-title":"Phys Ther"},{"issue":"9","key":"4030_CR15","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJM199503023320902","volume":"332","author":"JM Guralnik","year":"1995","unstructured":"Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower extremity function over the age of 70 years as a predictor of subsequent disability. NEJM. 1995;332(9):556\u201361.","journal-title":"NEJM"},{"issue":"2","key":"4030_CR16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","volume":"39","author":"D Podsiadlo","year":"1991","unstructured":"Podsiadlo D, Richardson S. The timed \"up & go\": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142\u20138.","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"4030_CR17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1123\/jpah.10.2.280","volume":"10","author":"ZB Cao","year":"2013","unstructured":"Cao ZB, Miyatake N, Aoyama T, Higuchi M, Tabata I. Prediction of maximal oxygen uptake from a 3-minute walk based on gender, age, and body composition. J Phys Act Health. 2013;10(2):280\u20137.","journal-title":"J Phys Act Health"},{"issue":"24","key":"4030_CR18","doi-asserted-by":"publisher","first-page":"2239:46","DOI":"10.1212\/WNL.0000000000001070","volume":"83","author":"AA Amato","year":"2014","unstructured":"Amato AA, Sivakumar K, Goyal N, David WS, Salajegheh M, Praestgaard J, et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology. 2014;83(24):2239:46.","journal-title":"Neurology"},{"issue":"4","key":"4030_CR19","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.ymthe.2017.02.015","volume":"25","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Sahenk Z, Al-Zaidy S, Rodino-Klapac LR, Lowes LP, Alfanop LN, et al. Follistatine gene therapy for sporadic inclusion body myositis improves functional outcomes. Mol Ther. 2017;25(4):870\u20139.","journal-title":"Mol Ther"},{"issue":"1","key":"4030_CR20","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41467-017-01486-4","volume":"8","author":"V Mariot","year":"2017","unstructured":"Mariot V, Joubert R, Hourde C, Feasson L, Hanna M, Muntoni F, et al. Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. Nat Commun. 2017;8(1):1859. https:\/\/doi.org\/10.1038\/s41467-017-01486-4.","journal-title":"Nat Commun"},{"issue":"5","key":"4030_CR21","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/WCO.0000000000000853","volume":"33","author":"KR Wagner","year":"2020","unstructured":"Wagner KR. The elusive promise of myostatin inhibitor for muscular dystrophy. Curr Opin Neurol. 2020;33(5):621\u20138.","journal-title":"Curr Opin Neurol"},{"issue":"10","key":"4030_CR22","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/j.biocel.2013.05.036","volume":"45","author":"O Schakman","year":"2013","unstructured":"Schakman O, Kalista S, Barbe C, Loumaye A, Thissen JP. Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol. 2013;45(10):2163\u201372.","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"4030_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12877-018-0770-y","volume":"18","author":"H Arrieta","year":"2018","unstructured":"Arrieta H, Rezola-Pardo C, Echeverria I, Iturburu M, Gi SM, Yanguas J, et al. Physical activity and fitness are associated with verbal memory, quality of life and depression among nursing home residents: preliminary data of a randomized controlled trial. BMC Geriatr. 2018;18(1):80.","journal-title":"BMC Geriatr"},{"issue":"Suppl","key":"4030_CR24","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1123\/ijsnem.11.s1.s111","volume":"11","author":"JN Schulte","year":"2001","unstructured":"Schulte JN, Yarasheski KE. Effects of resistance training on the rate of muscle protein synthesis in frail elderly people. Int J Sport Nutr Exerc Metab. 2001;11(Suppl):S111\u20138.","journal-title":"Int J Sport Nutr Exerc Metab"},{"issue":"5","key":"4030_CR25","first-page":"343","volume":"6","author":"KE Yarasheski","year":"2002","unstructured":"Yarasheski KE, Bhasin S, Sinha-Hikim I, Pak-Loduca J, Gonzalez-Cadavid NF. Serum myostatin-immunoreactive protein is increased in 60-92 year old women and men with muscle wasting. J Nutr Health Aging. 2002;6(5):343\u20138.","journal-title":"J Nutr Health Aging"},{"issue":"1\u20132","key":"4030_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00508-018-1386-0","volume":"131","author":"K Kerschan-Schindl","year":"2019","unstructured":"Kerschan-Schindl K, Ebenbichler G, F\u00f6ger-Samwald U, Leiss H, Gesslbauer C, Herceg M, et al. Rheumatoid arthritis in remission: decreased myostatin and increased serum levels of periostin. Wien Klin Wochenschr. 2019;131(1\u20132):1\u20137.","journal-title":"Wien Klin Wochenschr"},{"issue":"3","key":"4030_CR27","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/art.22433","volume":"56","author":"KA Rouster-Stevens","year":"2007","unstructured":"Rouster-Stevens KA, Langman CB, Prince HE, Seshadri R, Shore RM, Abbott K, et al. RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis. Arthritis Rheum. 2007;56(3):977\u201383.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"4030_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1080\/03009740701687226","volume":"37","author":"RA Santiago","year":"2008","unstructured":"Santiago RA, Silva CAA, Caparbo VF, Sallum AME, Pereira RMR. Bone mineral apparent density in juvenile dermatomyositis: the role of lean body mass and glucocorticoid use. Scan J Rheumatol. 2008;37(1):40\u20137.","journal-title":"Scan J Rheumatol"},{"issue":"11","key":"4030_CR29","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1055\/s-0042-110571","volume":"48","author":"T Komori","year":"2016","unstructured":"Komori T. Glucocorticoid signaling and bone biology. Horm Metab Res. 2016;48(11):755\u201363.","journal-title":"Horm Metab Res"},{"issue":"2","key":"4030_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/jcp.25091","volume":"231","author":"MJ Lee","year":"2016","unstructured":"Lee MJ, Lim E, Mun S, Bae S, Murata K, Ivashkiv LB, et al. Intravenous immunoglobulin (IVIG) attenuates TNF-induced pathologic bone resorption and suppresses osteoclastogenesis by inducing A20 expression. J Cell Physiol. 2016;231(2):449\u201358.","journal-title":"J Cell Physiol"},{"key":"4030_CR31","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.mce.2014.10.007","volume":"399","author":"N Ito","year":"2015","unstructured":"Ito N, Wijenayaka AR, Pideaux M, Kogawa M, Omsby T, Evdokiou A, et al. Regulation of FG23 expression in IDG-SW3 osteocytes and human bone by pro-inflammatory stimuli. Mole Cellular Endocrinol. 2015;399:208\u201318.","journal-title":"Mole Cellular Endocrinol"},{"issue":"1","key":"4030_CR32","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/ki.2015.290","volume":"89","author":"V David","year":"2016","unstructured":"David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V, et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 2016;89(1):135\u201346.","journal-title":"Kidney Int"},{"issue":"4","key":"4030_CR33","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/MNH.0000000000000232","volume":"25","author":"C Francis","year":"2016","unstructured":"Francis C, David V. Inflammation regulates fibroblast growth factor 23 production. Curr Opin Nephrol Hypertens. 2016;25(4):325\u201332.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"2","key":"4030_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2169\/internalmedicine.55.5507","volume":"55","author":"H Sato","year":"2016","unstructured":"Sato H, Kazama JJ, Murasawa A, Otani H, Abe A, Ito S, et al. Serum fibroblast growth factor 23 (FGF23) in patients with rheumatoid arthritis. Intern Med. 2016;55(2):121\u20136.","journal-title":"Intern Med"},{"issue":"1","key":"4030_CR35","first-page":"50","volume":"38","author":"A Alvarez-Cienfuegos","year":"2020","unstructured":"Alvarez-Cienfuegos A, Cantero-Nieto L, Garcia-Gomez JA, Robledo G, Gonzalez-Gay MA, Ortego-Centeno N. FGF23-klotho axis in patients with rheumatoid arthrits. Clin Exp Rheumatol. 2020;38(1):50\u20137.","journal-title":"Clin Exp Rheumatol"},{"key":"4030_CR36","doi-asserted-by":"crossref","unstructured":"Zhang B, Umbach AT, Chen H, Yan J, Fakhri H, Fajol, et al. Up-regulation of FGF23 release by aldosterone. Biochem Biophys Res Commun. 2016;470(2):384\u201390.","DOI":"10.1016\/j.bbrc.2016.01.034"},{"issue":"1","key":"4030_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0003-9993(00)90212-0","volume":"81","author":"G Wiesinger","year":"2000","unstructured":"Wiesinger G, Quittan M, Nuhr M, Volc-Platzer B, Ebenbichler G, Zehetgruber M, et al. Aerobic capacity in adult dermatomyositis\/polymyositis patients and healthy controls. Arch Phys Med Rehabil. 2000;81(1):1\u20135.","journal-title":"Arch Phys Med Rehabil"},{"issue":"3","key":"4030_CR38","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/rheumatology\/keq356","volume":"50","author":"M Regardt","year":"2011","unstructured":"Regardt M, Henriksson EW, Alexanderson LIE. Patients with polymyositis or dermatomyositis have reduced grip force and health-related quality of life in comparison with reference values: an observational study. Rheumatology. 2011;50(3):578\u201385.","journal-title":"Rheumatology."},{"issue":"11","key":"4030_CR39","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1136\/ard.2005.045690","volume":"65","author":"IM Bronner","year":"2006","unstructured":"Bronner IM, van der Meulen MFG, de Visser M, Kalmijn S, Venrooij v, Voskuyl AE, et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis. 2006;65(11):1456\u201361.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4030_CR40","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/rheumatology\/37.12.1338","volume":"37","author":"G Wiesinger","year":"1998","unstructured":"Wiesinger G, Quittan M, Graninger M, Seeber A, Ebenbichler G, Sturm B, et al. Benefit of 6 months long-term physical training in polymyositis\/dermatomyositis patients. Br J Rheumatol. 1998;37(12):1338\u201342.","journal-title":"Br J Rheumatol"},{"issue":"6","key":"4030_CR41","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3899\/jrheum.160997","volume":"44","author":"KS Berntsen","year":"2017","unstructured":"Berntsen KS, Tollisen A, Schwartz T, Kirkhus E, Aalokken TM, Lund MB, et al. Submaximal exercise capacity in juvenile dermatomyositis after longterm disease: the contribution of muscle, lung, and heart involvement. J Rheumatol. 2017;44(6):827\u201334.","journal-title":"J Rheumatol"},{"issue":"10","key":"4030_CR42","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1053\/rmed.2002.1363","volume":"96","author":"M Iriberri","year":"2002","unstructured":"Iriberri M, Galdiz JB, Gorostiza A, Ansola P, Jace C. Comparison of the distances covered during 3 and 6 min walking test. Respir Med. 2002;96(10):812\u20136.","journal-title":"Respir Med"},{"issue":"8","key":"4030_CR43","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s00296-018-4050-0","volume":"38","author":"N Mugii","year":"2018","unstructured":"Mugii N, Someya F. Cardiopulmonary factors affecting 6-min walk distance in patients with idiopathic inflammatory myopathies. Rheumatol Int. 2018;38(8):1443\u20138.","journal-title":"Rheumatol Int"},{"issue":"12","key":"4030_CR44","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al. EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76(12):1955\u201364.","journal-title":"Ann Rheum Dis"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-021-04030-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12891-021-04030-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-021-04030-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T23:28:55Z","timestamp":1612740535000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-021-04030-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,5]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4030"],"URL":"https:\/\/doi.org\/10.1186\/s12891-021-04030-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-37183\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-37183\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-37183\/v3","asserted-by":"object"}]},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,5]]},"assertion":[{"value":"17 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was performed after obtaining ethical approval from the regional ethics review board (Medical University of Vienna; 10052013). Each patient gave written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Peter Pietschmann has received research support and\/or honoraria from Amgen GmbH, Biomedica GmbH, DePuySynthes, Eli Lilly GmbH, Fresenius Kabi Austria, Meda Pharma\/Mylan GmbH, Shire Austria GmbH, TAmiRNA GmbH and UCB Pharma. All other authors have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}